
Gene mutations associated with early onset familial Alzheimer’s disease in China: An overview and current status
Author(s) -
Qin Qi,
Yin Yunsi,
Wang Yan,
Lu Yuanyuan,
Tang Yi,
Jia Jianping
Publication year - 2020
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.1443
Subject(s) - psen1 , presenilin , genetics , phenotype , mutation , disease , gene , biology , genotype phenotype distinction , genotype , gene mutation , bioinformatics , medicine , alzheimer's disease , pathology
Background Mutations of three causative genes, namely presenilin 1 ( PSEN1 ), presenilin 2 ( PSEN2 ), and amyloid precursor protein ( APP ), have been identified as the major causes of early‐onset familial Alzheimer's disease (EOFAD). The prevalence of causative gene mutations in patients with EOFAD has been reported in previous studies worldwide but remains unclear in China. The patients with these known mutations always show considerable clinical phenotypic variability. However, to date, there have been no detailed descriptions of the clinical phenotypes associated with these Chinese EOFAD mutations. Thus, the aim of this study was to describe all of the known mutations in three EOFAD causative genes and genotype–phenotype correlations in Chinese patients with EOFAD. Method We systematically searched the PubMed, MEDLINE, CNKI, VIP, and WAN‐FANG databases to find Chinese EOFAD mutations in reports from inception through May 2020. Result We identified 31 studies reporting mutations of three causative genes in China. 10 mutations in APP gene, 27 mutations in PSEN1 gene and six mutations in PSEN 2 were discovered in Chinese EOFAD. This review summarized all these probably pathogenic mutations as well as its clinical features. To the best of our knowledge, this is the first systemic review of causative gene mutations in patients with EOFAD in China. Conclusion The analysis of the genetic and clinical phenotype correlations in this review supports the idea that the clinical phenotype might be influenced by specific genetic defects. It also suggests genetic testing and genotype–phenotype correlations are important for the accurate diagnosis and for understanding disease‐associated pathways and might also improve disease therapy and prevention.